MX2021005784A - Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer. - Google Patents

Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer.

Info

Publication number
MX2021005784A
MX2021005784A MX2021005784A MX2021005784A MX2021005784A MX 2021005784 A MX2021005784 A MX 2021005784A MX 2021005784 A MX2021005784 A MX 2021005784A MX 2021005784 A MX2021005784 A MX 2021005784A MX 2021005784 A MX2021005784 A MX 2021005784A
Authority
MX
Mexico
Prior art keywords
cancer
hakai
selectively
compounds
effectively inhibit
Prior art date
Application number
MX2021005784A
Other languages
English (en)
Inventor
Badenas Federico Gago
Conde-Valvís Angélica Figueroa
Iglesias Olaia Antía Martínez
Castosa Raquel Carballo
Cabrera Álvaro Cortés
Pais Alba Casas
Original Assignee
Fund Profesor Novoa Santos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Profesor Novoa Santos filed Critical Fund Profesor Novoa Santos
Publication of MX2021005784A publication Critical patent/MX2021005784A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee una clase de compuestos, que incluye enantiómeros y sales farmacéuticamente aceptables de los mismos, que inhiben selectiva y efectivamente la ubiquitinación mediada por Hakai, de preferencia sin afectar los niveles de la proteína Hakai, representando de esta manera excelentes fármacos anti-cáncer útiles en el tratamiento de una variedad de cánceres, tales como carcinomas, en particular, tumores que surgen a partir de las capas epiteliales del tracto gastrointestinal incluyendo boca (cáncer oral), esófago, estómago, e intestinos delgado y grueso (tales como cáncer rectal o de colon). Esta también incluye cáncer de piel, glándula mamaria (cáncer de mama), cáncer de páncreas, cáncer de pulmón, cáncer de cabeza y cuello, cáncer hepático, cáncer de ovario, cáncer de cuello uterino, cáncer de útero, cáncer de vesícula biliar, cáncer de pene, y cáncer de vejiga urinaria (tal como cáncer renal, de próstata o de vejiga).
MX2021005784A 2018-11-15 2019-11-15 Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer. MX2021005784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382809.4A EP3653208A1 (en) 2018-11-15 2018-11-15 Compounds that selectively and effectively inhibit hakai-mediated ubiquitination, as anti-cancer drugs
PCT/EP2019/081522 WO2020099652A1 (en) 2018-11-15 2019-11-15 Compounds that selectively and effectively inhibit hakai-mediated ubiquitination, as anti-cancer drugs

Publications (1)

Publication Number Publication Date
MX2021005784A true MX2021005784A (es) 2021-09-23

Family

ID=64572276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005784A MX2021005784A (es) 2018-11-15 2019-11-15 Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer.

Country Status (9)

Country Link
US (1) US20220016080A1 (es)
EP (2) EP3653208A1 (es)
JP (1) JP2022507658A (es)
CN (1) CN113677340A (es)
AU (1) AU2019380035A1 (es)
CA (1) CA3119902A1 (es)
IL (1) IL283166A (es)
MX (1) MX2021005784A (es)
WO (1) WO2020099652A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909577A1 (en) * 2020-05-13 2021-11-17 Fundación Profesor Novoa Santos Ubiquitin-ligase inhibitors for the treatment of cancer
WO2023201374A1 (en) * 2022-04-15 2023-10-19 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124838A1 (en) * 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer

Also Published As

Publication number Publication date
CA3119902A1 (en) 2020-05-22
IL283166A (en) 2021-06-30
EP3880199A1 (en) 2021-09-22
CN113677340A (zh) 2021-11-19
JP2022507658A (ja) 2022-01-18
US20220016080A1 (en) 2022-01-20
EP3653208A1 (en) 2020-05-20
AU2019380035A1 (en) 2021-06-17
WO2020099652A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
EA201992418A1 (ru) Бициклические соединения и их применение в лечении рака
CY1119217T1 (el) Ενωση για την αγωγη του καρκινου
CY1118608T1 (el) Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6
JP2013534535A5 (es)
NZ724368A (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2021005784A (es) Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer.
EA201790547A1 (ru) Новые соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
MX2019011973A (es) Uso de la carrimicina y las sales farmaceuticamente aceptables de esta para la preparacion de medicamentos para el tratamiento y/o la prevencion de tumores.
CY1117687T1 (el) Adcs δουοκαρμυκινης που εμφανιζουν βελτιωμενη in vivo αντινεοπλασματικη δραστικοτητα
EA201790546A1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
RU2016108667A (ru) Комбинированная терапия для лечения рака
JP2015520753A5 (es)
RU2014128513A (ru) Раковый маркер и терапевтическая мишень
HRP20211652T1 (hr) Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze
JP2015512398A5 (es)
JP2017526662A5 (es)
Cuschieri et al. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma: let us move on to another era
RU2013134359A (ru) Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований
RU2016128396A (ru) Новые способы лечения рака
BR112014017053A2 (pt) atividade antitumoral de folatos reduzidos do tipo metileno- tetraidrofolato
RU2019123279A (ru) Этан-сульфонатная соль производного хинолина
EA201892194A1 (ru) Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
MX2020004431A (es) Anticuerpos y metodos de uso.